We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

A Contribution to the Chemotherapy of Bacterial Infections

Gerhard Domagk
Am J Dis Child. 1970;119(1):8-11. doi:10.1001/archpedi.1970.02100050010004.
Text Size: A A A
Published online


Hitherto it has been thought that only protozoan infections could be attacked chemotherapeutically. In the field of protozoan infections we do possess specific drugs, such as Germanin for Trypanosomal infections, Neostibosan for Kala-Azar, Plasmochin and Atabrine for malaria, and Salvarsan and its derivatives for spirochetal infections, especially syphilis.

Even moderately effective chemotherapy against coccal infections was heretofore unknown. Protozoa and spirochetes represent relatively well differentiated forms of life; and the more highly developed the infectious agent the more vulnerable to chemotherapeutic attack it appears to be. Morgenroth has made a beginning in the chemotherapy of pneumococcal infections, yet Optochin is effective only when directly applied to the infected area, as is the case with Vuzin—another hydrochinin derivative—in streptococcal infections. In the case of generalized infections, we have not seen clearly recognizable effects in our experimental animals with these preparations. Furthermore, the silver compounds recommended for the treatment of sepsis


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.